Pharvaris initiated with an Outperform at RBC Capital

RBC Capital initiated coverage of Pharvaris (PHVS) with an Outperform rating and $52 price target The firm believes the company’s deucrictibant can offer a “compelling profile” across the hereditary angioedema treatment spectrum. In a “crowded space,” the drug offers “strong efficacy, clean safety, and oral convenience that should help it differentiate from other established players,” the analyst tells investors in a research note. RBC expects a potential launch next year.